KR20230159531A - Kv7 통로 개방제의 전구약물 - Google Patents
Kv7 통로 개방제의 전구약물 Download PDFInfo
- Publication number
- KR20230159531A KR20230159531A KR1020237035814A KR20237035814A KR20230159531A KR 20230159531 A KR20230159531 A KR 20230159531A KR 1020237035814 A KR1020237035814 A KR 1020237035814A KR 20237035814 A KR20237035814 A KR 20237035814A KR 20230159531 A KR20230159531 A KR 20230159531A
- Authority
- KR
- South Korea
- Prior art keywords
- depression
- compound
- disease
- dystonia
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163470P | 2021-03-19 | 2021-03-19 | |
| US63/163,470 | 2021-03-19 | ||
| PCT/US2022/021059 WO2022198116A1 (en) | 2021-03-19 | 2022-03-20 | Prodrugs of kv7 channel openers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230159531A true KR20230159531A (ko) | 2023-11-21 |
Family
ID=83321210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237035814A Pending KR20230159531A (ko) | 2021-03-19 | 2022-03-20 | Kv7 통로 개방제의 전구약물 |
| KR1020237035629A Pending KR20230159506A (ko) | 2021-03-19 | 2022-03-20 | Kv7 통로 개방제의 전구약물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237035629A Pending KR20230159506A (ko) | 2021-03-19 | 2022-03-20 | Kv7 통로 개방제의 전구약물 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20240208896A1 (enExample) |
| EP (3) | EP4308544A4 (enExample) |
| JP (2) | JP2024511057A (enExample) |
| KR (2) | KR20230159531A (enExample) |
| CN (3) | CN117355503A (enExample) |
| AU (3) | AU2022240779A1 (enExample) |
| BR (2) | BR112023019074A2 (enExample) |
| CA (3) | CA3214270A1 (enExample) |
| IL (2) | IL306004A (enExample) |
| MX (2) | MX2023010978A (enExample) |
| WO (3) | WO2022198114A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115364229B (zh) * | 2022-09-26 | 2024-02-20 | 江苏海洋大学 | 一种用于预防或治疗疼痛的药物组合物 |
| CN118553447B (zh) * | 2024-07-30 | 2024-11-08 | 四川大学华西医院 | 动态惊恐障碍治疗方案推荐系统、治疗系统及存储介质 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4200259A1 (de) * | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
| JP2004115450A (ja) * | 2002-09-27 | 2004-04-15 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US20060004197A1 (en) * | 2004-07-02 | 2006-01-05 | Thomas Thrash | Sulfonamide-based compounds as protein tyrosine kinase inhibitors |
| US20090118285A1 (en) | 2006-02-07 | 2009-05-07 | H. Lundbeck A/S | Use of kcnq-openers for treating or reducing the symptoms of schizophrenia |
| EA201170230A1 (ru) | 2008-07-18 | 2011-08-30 | Вэлиант Фармасьютикалс Интернешнл | Препарат с модифицированной кинетикой высвобождения и способы его использования |
| GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| CN103073455B (zh) | 2011-10-25 | 2015-08-19 | 中国科学院上海药物研究所 | 一类新型的kcnq钾通道激动剂、其制备方法和用途 |
| WO2013179298A2 (en) * | 2012-04-23 | 2013-12-05 | Cadila Healthcare Limited | A process for preparation of phenyl carbamate derivative and polymorphic forms thereof |
| WO2016077724A1 (en) * | 2014-11-13 | 2016-05-19 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | (2-amino-4(arylamino)phenyl) carbamates |
| MX2018015251A (es) * | 2016-06-10 | 2019-04-25 | Scifluor Life Sciences Inc | Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado. |
| AU2019335070A1 (en) * | 2018-09-06 | 2021-05-13 | Ian Cooke | Method of treating a sleep breathing disorder |
-
2022
- 2022-03-20 EP EP22772332.7A patent/EP4308544A4/en active Pending
- 2022-03-20 KR KR1020237035814A patent/KR20230159531A/ko active Pending
- 2022-03-20 JP JP2023557407A patent/JP2024511057A/ja active Pending
- 2022-03-20 US US18/282,943 patent/US20240208896A1/en active Pending
- 2022-03-20 US US18/282,940 patent/US20240228434A1/en active Pending
- 2022-03-20 BR BR112023019074A patent/BR112023019074A2/pt unknown
- 2022-03-20 CN CN202280034761.1A patent/CN117355503A/zh active Pending
- 2022-03-20 WO PCT/US2022/021057 patent/WO2022198114A1/en not_active Ceased
- 2022-03-20 CN CN202280034079.2A patent/CN117295711A/zh active Pending
- 2022-03-20 IL IL306004A patent/IL306004A/en unknown
- 2022-03-20 IL IL306005A patent/IL306005A/en unknown
- 2022-03-20 WO PCT/US2022/021059 patent/WO2022198116A1/en not_active Ceased
- 2022-03-20 EP EP22772331.9A patent/EP4308543A4/en active Pending
- 2022-03-20 AU AU2022240779A patent/AU2022240779A1/en active Pending
- 2022-03-20 KR KR1020237035629A patent/KR20230159506A/ko active Pending
- 2022-03-20 CA CA3214270A patent/CA3214270A1/en active Pending
- 2022-03-20 WO PCT/US2022/021058 patent/WO2022198115A1/en not_active Ceased
- 2022-03-20 MX MX2023010978A patent/MX2023010978A/es unknown
- 2022-03-20 CA CA3214084A patent/CA3214084A1/en active Pending
- 2022-03-20 BR BR112023019077A patent/BR112023019077A2/pt unknown
- 2022-03-20 US US18/282,934 patent/US20240300894A1/en active Pending
- 2022-03-20 CA CA3214305A patent/CA3214305A1/en active Pending
- 2022-03-20 EP EP22772333.5A patent/EP4308545A4/en active Pending
- 2022-03-20 JP JP2023557288A patent/JP7897863B2/ja active Active
- 2022-03-20 CN CN202280034756.0A patent/CN117321031A/zh active Pending
- 2022-03-20 AU AU2022239618A patent/AU2022239618A1/en active Pending
- 2022-03-20 AU AU2022237675A patent/AU2022237675A1/en active Pending
- 2022-03-20 MX MX2023010976A patent/MX2023010976A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7493635B2 (ja) | Ｍｇａｔ２阻害活性を有する縮合環誘導体 | |
| JP6873433B2 (ja) | タンパク質分解のイミド系修飾因子および関連の使用方法 | |
| KR880000042B1 (ko) | 신규 유기 아마이드 화합물의 제법 | |
| KR20210134351A (ko) | 통합 스트레스 반응 경로의 억제제 | |
| KR20230022215A (ko) | 미토콘드리아 기능장애, 암 및 섬유증의 치료에 사용하기 위한 USP30 억제제로서 1-(5-(2-시아노피리딘-4-일)옥사졸-2-카보닐)-4-메틸헥사하이드로피롤로[3,4-b]피롤-5(1H)-카보니트릴 | |
| KR20230159506A (ko) | Kv7 통로 개방제의 전구약물 | |
| JP2020111571A (ja) | Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物 | |
| US8765953B2 (en) | Compounds and methods for the treatment of pain and other diseases | |
| US20130338116A1 (en) | Compounds and methods for the treatment of pain and other diseases | |
| WO2017195138A1 (en) | Small molecule n-(alpha-peroxy) carbazole compounds and methods of use | |
| US9505743B2 (en) | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases | |
| WO2024178425A1 (en) | Hydroxyalkyl and methoxyalkyl tryptamines | |
| WO2025019454A2 (en) | Substituted ergolines | |
| KR100267707B1 (ko) | Nmda 수용체 길항제로 작용하는 4-치환-퀴놀린-2-카복실산 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |